Back

An open-label extension study of aficamten for Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy: 48-week results

10 May 2026 (10:30 - 11:30)
Organised by: Logo
Congress Presentation Part of: ePosters in myocardial disease - hypertrophic cardiomyopathy (1) Hypertrophic Cardiomyopathy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Ms Yun Huang

Shanghai (China)

8 More presentations in this session

Presentation thumbnail
Echocardiographic predictors of acute hemodynamic response to right ventricular pacing in hypertrophic obstructive cardiomyopathy
Doctor P. Tangkongpanich (Bangkok, TH)
Abstract Slides
Presentation thumbnail
Predicting the final diagnosis in patients with suspected amyloid cardiomyopathy referred for tissue biopsy
Doctor A. Aimo (Pisa, IT)
Abstract Slides
Presentation thumbnail
Patient trajectories and disease progression in transthyretin amyloid cardiomyopathy: insights from the HANSE ATTR-TRACK real-world registry
Doctor D. Jurczyk (Luebeck, DE)
Abstract Slides
Presentation thumbnail
Predictors of atrial fibrillation in hypertrophic cardiomyopathy: insights from a regional hospital experience
Doctor A. Martins (Leiria, PT)
Abstract Slides
Presentation thumbnail
Genotype-driven differences in the phenotype and prognosis of patients with hypertrophic cardiomyopathy
Doctor A. Martins (Leiria, PT)
Abstract Slides

Access the full session

Session thumbnail
ePosters in myocardial disease - hypertrophic cardiomyopathy (1)

The Event

Event poster

Heart Failure 2026

10 May 2026 10:30 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources